A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
Recruiting · Phase 3 · NCT07382167
Conditions: Chronic Idiopathic Constipation (CIC)
At a glance
- Research payments reported, 2025
- $183,250
- U.S. investigators named
- 13
- Sites paid
- 14
- Planned or actual enrollment
- 692
About the trial
- Sponsor
- Ardelyx
- Tested
- Tenapanor 5 mg BID (drug), Tenapanor 25 mg BID (drug), Tenapanor 50 mg BID (drug), Placebo (drug)
- Dates
- Started 2026-01-13; completion 2027-06-04
- Results posted
- Not yet
This is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess the safety and efficacy of tenapanor (5 mg, 25mg, and 50 mg) in adult patients with Chronic Idiopathic Constipation (CIC) when administered twice daily for 26 consecutive weeks.
From ClinicalTrials.gov, last updated 2026-06-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ardelyx, Inc. reported $183,250 in research payments for this study in 2025 (14 payments).
Products named: Ibsrela
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Johnathan D. Goodwin, M.D. Gastroenterology · North Little Rock, AR
- Anita Kohli, MD Infectious Disease · Chandler, AZ
- Joseph L. Lillo, DO, FNLA, FAPCR Family Medicine · Scottsdale, AZ
- Hessam Aazami, M.D. General Practice · Canoga Park, CA
- Erick H. Alayo, M.D. Gastroenterology · Chula Vista, CA
- Soheil P. Hekmat, MD Internal Medicine · Inglewood, CA
- David B. Mishkin, D.O. Family Medicine · Fort Lauderdale, FL
- Paresh Patel, MD Gastroenterology · Kansas City, MO
- Roy J. Peters, M.D. Internal Medicine · High Point, NC
- Robby Ann Quintos, MD Internal Medicine · Las Vegas, NV
- John D. Gabriel, MD Family Medicine · North Richland Hills, TX
- Sefanit Gebretsadik, M.D Internal Medicine · Frisco, TX
- Kristen Holtz, DO Family Medicine · Hampton, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Focushope Clinical Research Inc $17,000
- Kansas City Research Institute LLC $16,000
- Charlottesville Medical Research Center LLC $16,000
- Excel Clinical Research LLC $15,000
- Zenos Clinical Research LLC $15,000
- Acclaim Clinical Research LLC $15,000
- 310 Clinical Research LLC $15,000
- The Institute for Liver Health II LLC $12,550
- Proactive Clinical Research LLC $11,500
- Erick H Alayo Medical Corporation $11,100
- North Hills Medical Research Inc $11,000
- Arkansas Gastroenterology $9,700
- Peters Medical Research LLC $9,400
- Elite Clinical Studies LLC $9,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.